Hipertiroidismo y sistema cardiovascular Bases fisiopatológicas y su ...

INSUFICIENCIA CARDIACA
Vol. 5, Nº 4, 2010
177 D Mantilla y col.
Hipertiroidismo y sistema cardiovascular
bined therapy using propylthiouracil and potassium perchlorate.
Aust NZ J Med 1988;18:37-44.
122. Donaghue KC, Clarke P, Hooper MJ. Amiodarone. The dilemma
of hyperthyroxinemia and the treatment of thyrotoxicosis. Med J
Aust 1985;142:594-596.
Wu SY, Shyh TP, Chopra IJ, Huang HW, Chy PC. Comparison of
123.
sodium ipodate (Oragrafin) and propylthiouracil in early treatment
of hyperthyroidism. J Clin Endocrinol Metab 1982;54:630-634.
Shen DC, Wu SY, Chopra IJ, et al. Long term treatment of Graves’
124.
hyperthyroidism with sodium ipodate. J Clin Endocrinol Metab
1985;61:723-727.
Hopra IJ, Van Herle AJ, Korenman SG, Viosca S, Younai S. Use
125.
of sodium ipodate in management of hyperthyroidism in subacute
thyroiditis. J ClinEndocrinol Metab 1995;80:2178-2180.
126. Awin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism:
the early history. Thyroid 1997;7:163-176.
127. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden
EA. A randomized comparison of radioiodine dose in Graves’
hyperthyroidism. J Clin Endocrinol Metab 2003;88:978-983.
Crooks J, Buchanan WW, Wayne EJ, MacDonald E. Effect of
128.
pretreatment with methylthiouracil on results of 131I therapy. Br
Med J 1960;1:151-154.
Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil
129.
before radioactive iodine is associated with a higher treatment
failure rate than therapy with radioactive iodine alone in Graves’
disease. Thyroid 1995;5:243-247.
130. Berens S, Bernstein R, Robbins J, Wolff J. Antithyroid effects of
lithium. J Clin Invest 1970;49:1357-1367.
131. Briere J, Pousset G, Darsy et Guinet P. The advantage of lithium
in association with 131I in the treatment of functioning metastasis
of the thyroid cancer. Ann Endocrinol 1974;35:281-282.
Gershengorn MC, Izumi M, Robbins J. Use of lithium as an
132.
adjunct to radioiodine therapy of thyroid carcinoma. J Clin Endocrinol
Metab 1976;42:105-111.
Pons F, Carrio I, Estorch M, Ginjaume M, Pons J, Milian R.
133.
Lithium as an adjunct of iodine-131 uptake when treating patients
with well-differentiated thyroid carcinoma. Clin Nucl Med
1987;12:644-647.
Bal CS, Kumar A, Chandra P. Effect of iopanoic acid on radioiodine
134.
therapy of hyperthyroidism: long-term outcome of a randomized
controlled trial J. Clin Endocrinol Metab 2005;90:6536-6540.
Rubin L. Diagnosis and management of pulmonary artery hy-
135.
pertension: ACCP evidence-based clinical practice guidelines.
Chest 2004;126:7-10.
136. Arroliga A, Dweik R, Rafanan A. Primary pulmonary hypertension
and thyroid disease. Letter to the editor. Chest 2000;118:1224
137. Du L, Sullivan C, Chu D. Signaling molecules in nonfamilial
pulmonary hypertension. N Engl J Med 2003;348:500-509.
138. Paolini R, Armigliato M, Zamboni S. Pulmonary hypertension
in systemic diseases. Curr Drug Targets Inflamm Allergy
2004;3:459-467.
Vargas F, Rivas A, Osuna A. Effects of methimazole in the early
139.
and established phases of Ng-nitro-arginine methyl ester hypertension.
Eur J Endocrinol 1996;135:506-513.
Marvisi M, Zambrelli P, Brianti M, et al. Pulmonary hypertension
140.
is frequent in hyperthyroidism and normalizes after therapy. Eur
J Inter Med 2006;17:267-271.
141. Ardeshir S, Burstein S, Guy W, et al. Pulmonary hypertension in
men with thyrotoxicosis. Respiration 2005;72;990-994.
142. Martí V, Ballester M, Rigla M, Narula J, Berna L, Pons-Llado G,
Carrió I, Carreras F, Webb SM. Myocardial damage does not occur
in untreated hyperthyroidism unless associated with congestive
heart failure. Am Heart J 1997;134(6):1133-1137.
O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL,
143.
Wolfson Jr SK. Carotid-artery intima and media thickness as a
risk factor for myocardial infarction and stroke in older adults.
Cardiovascular Health Study Collaborative Research Group. N
Engl J Med 1999;340:14-22.
Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M,
144.
Sharrett AR, Clegg LX. Association of coronary heart disease
incidence with carotid arterial wall thickness and major risk
factors: the Atherosclerosis Risk in Community (ARIC) Study,
1987-1993. Am J Epidemiol 1997;146:483-494.
Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E,
145.
Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive
of incident clinical stroke: the Atherosclerosis Risk in Communities
(ARIC) Study. Am J Epidemiol 2000;151:478-487.
146. Völzke H, Robinson DM, Schminke U, Lüdemann J, Rettig R,
Felix SB, et al. Thyroid function and carotid wall thickness. J Clin
Endocrinol Metab 2004;89(5):2145-2149.
Garcia-Estan J, Atucha NM, Quesada T, Vargas F. Involve-
147.
ment of the renin-angiotensin system in the reduced pressure
natriuresis response of hyperthyroid rats. Am J Physiol
1995;268:E897-E901.
Paul M, Ganten D. The molecular basis of cardiovascular hyper-
148.
trophy. The role of the renin-angiotensin system. J Cardiovasc
Pharmacol 1992;19:S51-S58.
Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta
149.
T. Angiotensin II stimulates collagen synthesis in cultured vascular
smooth muscle cells. J Hypertens 1991;9:17-22.
Sernia C, Marchant C, Brown L, Hoey A. Cardiac angiotensin
150.
system receptors in experimental hyperthyroidism in dogs. Cardiovasc
Res 1993;27:423-428.
Inaba M, Henmi Y, Kumeda Y, Ueda M, Nagata M, Emoto M,
151.
Ishikawa T, Ishimura E, Nishizawa Y. Increased stiffness in
common carotid artery in hyperthyroid Graves’ disease patients.
Biomed Pharmacother 2002;56:241-246.
Czarkowski M, Hilgertner L, Powalowski T, Radomski D. The
152.
stiffness of the common carotid artery in patients with Graves’
disease. Int Angiol 2002;21:152-157.
Glagov S, Vito R, Giddens DP, Zarins CK. Micro-architecture
153.
and composition of artery walls: relationships to location, diameter
and the distribution of mechanical stress. J Hypertens
1992;10:S101-S104.
Squizzato A, Gerdes VEA, Brandjes DPM, Buller HR, Stam
154.
J. Thyroid diseases and cerebrovascular disease. Stroke
2005;36:2302-2310.
155. Hofbauer LC, Heufelder AE. Coagulation disorders in thyroid
diseases. Eur J Endocrinol 1997;136:1-7.
156. Marongiu F, Cauli C, Mariotti S. Thyroid, hemostasis and thrombosis.
J Endocrinol Invest 2004;27:1065-1071.
157. Shih CH, Chen SL, Yen CC, Huang YH, Chen CD, Lee YS,
Lin KH. Thyroid hormone receptor dependent transcriptional
regulation of fibrinogen and coagulation proteins. Endocrinology
2004;145:2804-2814.
Squizzato A, Romualdi E, Büller HR, Gerdes VEA. Thyroid dys-
158.
function and effects on coagulation and fibrinolysis: a systematic
review. J Clin Endocrinol Metab 2007;92:2415-2420.
Rogers II JS, Stanley RS. Factor VIII activity in normal
159.
volunteers receiving oral thyroid hormone. J Lab Clin Med
1983;102:444-449.
160. Awadi MH, Ho L, Dejong DC. Effect of TRH on plasma arginin
vasopressin. Horm Res 1984;19:91-96.
161. Rem C. Blood coagulation, fibrinolytic activity and lipid profile in
subclinical thyroid disease: subclinical hyperthyroidism increases
plasma factor X activity. Clin Endocrinol (Oxf) 2006;64:323-329.
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, et al.
162.
ACC/AHA/ESC 2006 Guidelines for the management of patients
with atrial fibrillation. A Report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines and the European Society of Cardiology Committee
for Practice Guidelines (Writing Committee to Revise the 2001
Guidelines for the Management of Patients With Atrial Fibrillation):
developed in collaboration with the European Heart
Rhythm Association and the Heart Rhythm Society. Circulation
2006;114:e257-e354.
Umpierrez G, Challapalli S, Patterson C. Congestive heart failure
163.
due to reversible cardiomyopathy in patients with hyperthyroidism.
AMJ Med Sci 1995;310:99-102.
Goldman L, Sahlas D, Sami M. A case of thyrotoxicosis
164.
and reversible systolic cardiac dysfunction. Can J Cardiol
1999;15:811-814.
Kantharia B, Richards H, Battaglia J. Reversible dilated car-
165.
diomyopathy: an unusual case of thyrotoxicosis. AM Heart J
1995;129:1030-1032.
Merce J, Ferras S, Oltra C, et al. Cardiovascular abnormalities in
166.
hyperthyroidism: a prospective Doppler echocardiographic study.
Am J Med 2005;118:126-131.
167. Canaris G, Manowitz N, Mayor G, Ridgway E. The Colorado thyroid
disease prevalence study. Arch Intern Med 2000;160:526-530.
168. Ganong WF. Fisiología médica. 16ª ed. México: Manual Moderno.
1998:355-372.
169. Froeschl M, Haddad H, Commons AS, Veinot JP. Thyrotoxicosis: an
uncommon cause of heart failure. Cardiov Pathol 2005:14:24-27.